Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Italy: Corlopam.

North America

Canada: Corlopam; USA: Corlopam, Fenoldopam.

Drug combinations


Fenoldopam Mesylate: C~16~H~16~ClNO~3~ CH~4~SO~3~. Mw: 401.86. (1) 1H-3-Benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-, methanesulfonate; (2) 6-Chloro-2,3,4,5-tetrahydro-1-(p-hydroxyphenyl)-1H-3-benzazepine-7,8-diol methanesulfonate. CAS-67227-57-0;CAS-67227-56-9 (fenoldopam)(1984).

Pharmacologic Category

Hypotensive Agents; Direct Vasodilators, Dopamine Agonist. (ATC-Code: C01CA19).

Mechanism of action

A selective postsynaptic dopamine agonist (D~1~-receptors) which exerts hypotensive effects by decreasing peripheral vasculature resistance with increased renal blood flow, diuresis, and natriuresis. Six times as potent as dopamine in producing renal vasodilitation. Has minimal adrenergic effects.

Therapeutic use

Treatment of severe hypertension (up to 48 hours in adults), including in renal compromise. Short-term (up to 4 hours) blood pressure reduction in pediatric patients.

Pregnancy and lactiation implications

Fetal harm not observed in animal studies. Use during pregnancy only if clearly needed.

Unlabeled use


Hypersensitivity of fenoldopam or any component of the formulation.

Warnings and precautions

Tachycardia can occur (dose-related). Use with caution in angina (can increase myocardial oxygen demand with tachycardia), in open-angle glaucoma or intraocular hypertension, or in increased intracranial pressure. Contains sulfites (may cause allergic reaction in susceptible individuals). For continuous infusion only. Hypotension can occur.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart